Precision BioSciences Q3 revenue $0.6M, net loss $16.4M; PBGENE-HBV enters clinic

PRECISION BIOSCIENCES INC

2024-Q3 EPS reported $3.78 revenue$68,058,000

Revenue $0.6M down from $13.1M YoY; net loss $16.4M ($2.25/share) vs $8.1M loss in Q3 2023.
Cash $121.3M sufficient into H2 2026, supplemented by $22.5M loan from Banc of California (maturing June 2027).
PBGENE-HBV CTA approved in Moldova; patient screening underway; Phase 1 data expected in 2025.
PBGENE-3243 (mitochondrial disease) IND/CTA expected in 2025; regained rights to three Prevail programs under assessment.
Appointed Dr. Murray Abramson SVP Head of Clinical Development and John Fry as Strategic Clinical Advisor for hepatitis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.